Growth Metrics

Amphastar Pharmaceuticals (AMPH) Other Non-Current Liabilities: 2014-2024

Historic Other Non-Current Liabilities for Amphastar Pharmaceuticals (AMPH) over the last 11 years, with Dec 2024 value amounting to $20.9 million.

  • Amphastar Pharmaceuticals' Other Non-Current Liabilities rose 8.26% to $29.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.3 million, marking a year-over-year increase of 8.26%. This contributed to the annual value of $20.9 million for FY2024, which is 7.80% down from last year.
  • Latest data reveals that Amphastar Pharmaceuticals reported Other Non-Current Liabilities of $20.9 million as of FY2024, which was down 7.80% from $22.7 million recorded in FY2023.
  • Amphastar Pharmaceuticals' 5-year Other Non-Current Liabilities high stood at $22.7 million for FY2023, and its period low was $13.2 million during FY2020.
  • Over the past 3 years, Amphastar Pharmaceuticals' median Other Non-Current Liabilities value was $20.9 million (recorded in 2024), while the average stood at $19.4 million.
  • Per our database at Business Quant, Amphastar Pharmaceuticals' Other Non-Current Liabilities surged by 55.98% in 2023 and then dropped by 7.80% in 2024.
  • MRY analysis of 5 years shows Amphastar Pharmaceuticals' Other Non-Current Liabilities stood at $13.2 million in 2020, then grew by 18.48% to $15.7 million in 2021, then decreased by 6.95% to $14.6 million in 2022, then soared by 55.98% to $22.7 million in 2023, then fell by 7.80% to $20.9 million in 2024.
  • Its Other Non-Current Liabilities stands at $20.9 million for FY2024, versus $22.7 million for FY2023 and $14.6 million for FY2022.